Phase III trial of capecitabine (Xeloda (R)) plus bevacizumab (Avastin (TM)) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane.
Publication
, Conference
Miller, KD; Rugo, HS; Cobleigh, MA; Marcom, PK; Chap, LI; Holmes, FA; Fehrenbacher, L; Overmoyer, BA; Reimann, JD; Vassel, AV; Langmuir, VK
Published in: BREAST CANCER RESEARCH AND TREATMENT
December 1, 2002
Duke Scholars
Published In
BREAST CANCER RESEARCH AND TREATMENT
ISSN
0167-6806
Publication Date
December 1, 2002
Volume
76
Start / End Page
S37 / S37
Location
SAN ANTONIO, TEXAS
Publisher
KLUWER ACADEMIC PUBL
Conference Name
25th San Antonio Breast Cancer Symposium
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Miller, K. D., Rugo, H. S., Cobleigh, M. A., Marcom, P. K., Chap, L. I., Holmes, F. A., … Langmuir, V. K. (2002). Phase III trial of capecitabine (Xeloda (R)) plus bevacizumab (Avastin (TM)) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. In BREAST CANCER RESEARCH AND TREATMENT (Vol. 76, pp. S37–S37). SAN ANTONIO, TEXAS: KLUWER ACADEMIC PUBL.
Miller, K. D., H. S. Rugo, M. A. Cobleigh, P. K. Marcom, L. I. Chap, F. A. Holmes, L. Fehrenbacher, et al. “Phase III trial of capecitabine (Xeloda (R)) plus bevacizumab (Avastin (TM)) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane.” In BREAST CANCER RESEARCH AND TREATMENT, 76:S37–S37. KLUWER ACADEMIC PUBL, 2002.
Miller KD, Rugo HS, Cobleigh MA, Marcom PK, Chap LI, Holmes FA, et al. Phase III trial of capecitabine (Xeloda (R)) plus bevacizumab (Avastin (TM)) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. In: BREAST CANCER RESEARCH AND TREATMENT. KLUWER ACADEMIC PUBL; 2002. p. S37–S37.
Miller, K. D., et al. “Phase III trial of capecitabine (Xeloda (R)) plus bevacizumab (Avastin (TM)) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane.” BREAST CANCER RESEARCH AND TREATMENT, vol. 76, KLUWER ACADEMIC PUBL, 2002, pp. S37–S37.
Miller KD, Rugo HS, Cobleigh MA, Marcom PK, Chap LI, Holmes FA, Fehrenbacher L, Overmoyer BA, Reimann JD, Vassel AV, Langmuir VK. Phase III trial of capecitabine (Xeloda (R)) plus bevacizumab (Avastin (TM)) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. BREAST CANCER RESEARCH AND TREATMENT. KLUWER ACADEMIC PUBL; 2002. p. S37–S37.
Published In
BREAST CANCER RESEARCH AND TREATMENT
ISSN
0167-6806
Publication Date
December 1, 2002
Volume
76
Start / End Page
S37 / S37
Location
SAN ANTONIO, TEXAS
Publisher
KLUWER ACADEMIC PUBL
Conference Name
25th San Antonio Breast Cancer Symposium
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences